Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 13/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 10/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.39 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17310279 | 0.88 | MAPK10 (0.39) | MAPK10MAPK8DYRK1AEPHB3GSK3B | |
| SCHEMBL2273364 | 0.83 | MAPK10 (0.43) | MAPK10MAPK8 | |
| SCHEMBL12369463 | 0.82 | CA12 (0.46) | MAPK10MAPK8 | |
| SCHEMBL2272272 | 0.81 | MAPK10 (0.39) | MAPK10MAPK8 | |
| SCHEMBL2274347 | 0.80 | ADRA1D (0.42) | MAPK10MAPK8MAPT | |
| SCHEMBL2273841 | 0.80 | MAPK10 (0.42) | MAPK10MAPK8 | |
| SCHEMBL12394597 | 0.79 | MAPK10 (0.42) | MAPK10MAPK8 | |
| SCHEMBL2276078 | 0.79 | MAPK10 (0.42) | MAPK10MAPK8 | |
| SCHEMBL12369465 | 0.79 | MAPK10 (0.47) | MAPK10MAPK8 | |
| SCHEMBL12369453 | 0.79 | MAPK10 (0.43) | MAPK10MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994196-B2 | Indazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | claimed |
| US-7994196-B2 | Indazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7994196-B2 | Indazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7994196-B2 | Indazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | CYP3A5, CYP3A43, TP53 | MAPK10 3940/4885MAPK8 3551/4885DYRK1A 3173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.